Search results for "TUMOR CELLS"

showing 10 items of 663 documents

Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway.

2001

Hepatitis C virus (HCV) persists in the majority of infected individuals and is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Chronic hepatitis C is currently treated with interferon (IFN)-α or with a combination of IFN-α and ribavirin. The availability of an HCV replicon system (Lohmann et al., Science 285, 110–113, 1999) allowed the investigation of the effects of IFN on genuine HCV replication in cultured cells. It is shown here that IFN-α inhibits subgenomic HCV RNA replication in HuH-7 human hepatoma cells. Immunofluorescence, Western blot and Northern blot analysis revealed that levels of both HCV protein and replicon RNA were reduced after treatme…

Myxovirus Resistance ProteinsHepatitis C virusHepacivirusBiologyViral Nonstructural Proteinsmedicine.disease_causeAntiviral Agentschemistry.chemical_compoundInterferonGTP-Binding ProteinsVirologymedicineTumor Cells CulturedHumansRepliconNorthern blotSubgenomic mRNADose-Response Relationship DrugRibavirinvirus diseasesRNAInterferon-alphaProteinsVirologyMolecular biologydigestive system diseasesNS2-3 proteasechemistryRNA ViralRepliconmedicine.drugThe Journal of general virology
researchProduct

In Vivo Observations on Tumor Invasion

1989

Tumor invasion in vivo is a very complex and dynamic process which depends upon a variety of interactions between heterogeneous tumor cell populations and the different cellular and extracellular components of the host tissue. This situation cannot be reproduced even in the most sophisticated in vitro system. On the other hand, there is at present no method available for a direct and dynamic observation of tumor invasion deep in the nontransparent living tissue, so that all evidence has to be derived from indirect observations made on the basis of static morphology. But all these limitations do not deny the potential value of in vivo investigations in following the natural course of tumor i…

Natural courseTumor differentiationIn vivoIn vitro systemCancer researchTumor cellsBiologyHost tissueInvasion front
researchProduct

Plexin-B1 and Semaphorin 4D Cooperate to Promote Perineural Invasion in a RhoA/ROK-Dependent Manner

2012

Perineural invasion (PNI) is a tropism of tumor cells for nerve bundles located in the surrounding stroma. It is a pathological feature observed in certain tumors, referred to as neurotropic malignancies, that severely limits the ability to establish local control of disease and results in pain, recurrent growth, and distant metastases. Despite the importance of PNI as a prognostic indicator, its biological mechanisms are poorly understood. The semaphorins and their receptors, the plexins, compose a family of proteins originally shown to be important in nerve cell adhesion, axon migration, and proper central nervous system development. Emerging evidence has demonstrated that these factors a…

Nervous systemPathologymedicine.medical_specialtyCell typeanimal structuresRHOANervous System NeoplasmsTransplantation HeterologousPerineural invasionRetraction NoticeMice NudeNerve Tissue ProteinsReceptors Cell SurfaceSemaphorinsPathology and Forensic Medicine03 medical and health sciencesMice0302 clinical medicineSemaphorinAntigens CDCell MovementCell Line TumorSettore BIO/10 - BiochimicamedicineAnimalsHumansNeoplasm InvasivenessAxonRNA Small InterferingCell adhesion030304 developmental biologyMice Knockout0303 health sciencesbiologyDrug SynergismAxonsTransplantationMice Inbred C57BLmedicine.anatomical_structure030220 oncology & carcinogenesisembryonic structuresbiology.proteinCancer researchperineural invasion tumor cells Rho kinase-dependent manner plexin B1rhoA GTP-Binding ProteinNeoplasm TransplantationSignal TransductionThe American Journal of Pathology
researchProduct

Differentiation of Y79 cells induced by prolonged exposure to insulin

1997

Y79 human retinoblastoma cells are known to contain receptors for both insulin and insulin-like growth factors (IGFs), to produce these cytokines and release them in the culture medium. Previously we have demonstrated that IGFs and insulin stimulate Y79 cell proliferation through the involvement of type I IGF receptor and Insulin Receptor Substrate 1 (IRS-1). This paper studies the effect of prolonged exposure to insulin on Y79 cells. Cells grown for 10 days in the presence of insulin were reseeded and incubated once more with insulin. In the reseeded cells proliferation lowered and morphological changes appeared. After 10 days of reseeding, cells stopped proliferating and showed long ramif…

NeuronsTime FactorsEye NeoplasmsRetinoblastomaCell DifferentiationDNADopamine beta-HydroxylaseCholine O-AcetyltransferaseGlobinsDifferentiationGlial Fibrillary Acidic ProteinNeuritesTumor Cells CulturedHumansInsulinBiomarkersCell DivisionThymidine
researchProduct

Uridine uptake inhibition as a cytotoxicity test for a human hepatoma cell line (HepG2 cells): comparison with the neutral red assay

2001

International audience; This study describes a sensitive microassay for measuring cytotoxicity based on the degree of inhibition of RNA synthesis in HepG2 cells. RNA synthesis is measured by the kinetic uptake of radiolabeled uridine. A large number of compounds were tested in a wide range of concentrations. The concentration required to induce 50% inhibition of HepG2 uridine uptake rates (IC50) was determined for each compound and used to rank its potency. These IC50s were compared with IC50s measured with the neutral red assay. 2-acetylaminofluorene, benzo[a]pyrene and methylnitrosourea were not cytotoxic in the neutral red assay. Uridine uptake was always inhibited at lower concentrations…

Neutral redCarcinoma Hepatocellular[SDV.TOX.TCA]Life Sciences [q-bio]/Toxicology/Toxicology and food chainToxicologyXenobiotics03 medical and health scienceschemistry.chemical_compoundInhibitory Concentration 500302 clinical medicineNeutral redToxicity TestsTumor Cells CulturedPotencyCytotoxic T cellHumansBenzopyrenesCytotoxicityColoring AgentsUridine030304 developmental biology0303 health sciencesReproducibility of ResultsMethylnitrosourea2-AcetylaminofluoreneUridine uptakeIn vitroUridineKineticschemistryBiochemistryCytotoxicity-helpG2 cell line[SDV.TOX.TCA] Life Sciences [q-bio]/Toxicology/Toxicology and food chain030220 oncology & carcinogenesisToxicityCarcinogensHepatocytesPyreneRNARegression AnalysisWater Pollutants Chemical
researchProduct

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast canc…

2021

Different immunohistochemical programmed death-ligand 1 (PD-L1) assays and scorings have been reported to yield variable results in triple-negative breast cancer (TNBC). We compared the analytical concordance and reproducibility of four clinically relevant PD-L1 assays assessing immune cell (IC) score, tumor proportion score (TPS), and combined positive score (CPS) in TNBC. Primary TNBC resection specimens (n = 104) were stained for PD-L1 using VENTANA SP142, VENTANA SP263, DAKO 22C3, and DAKO 28–8. PD-L1 expression was scored according to guidelines on virtual whole slide images by four trained readers. The mean PD-L1 positivity at IC-score ≥1% and CPS ≥1 ranged between 53% and 75% with th…

OncologyCPS combined positive scoreTC tumor cellsICI immune checkpoint inhibitorTriple Negative Breast NeoplasmsB7-H1 AntigenMedicineHER2 human epidermal growth factor receptor 2Triple-negative breast cancerRC254-282ICC intraclass correlation coefficientbiologyNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineMSI microsatellite instabilityImmunohistochemistrypCR pathological complete responsePFS progression-free survivalImmunohistochemistryOriginal ArticleIC-ScoreIC immune cellsIHC immunohistochemistryProgrammed deathPD-L1medicine.medical_specialtyConcordanceTNBC triple-negative breast cancerOS overall survivalBreast cancerTriple-negative breast cancerPD-L1Internal medicineTPS tumor proportion scoreBiomarkers TumorHumansProgrammed death-ligand 1Reproducibilitybusiness.industryReproducibility of Resultsmedicine.diseaseITT intention to treatCI confidence intervalPD-L1 programmed death-ligand 1biology.proteinSurgeryCPSbusinessKappaTMB tumor mutational burdenBreast
researchProduct

Liquid biopsies in lung cancer: The new ambrosia of researchers

2014

Abstract: In the last decades the approach to cancer patient management has been deeply revolutionized. We are moving from a "one-fits-all" strategy to the "personalized medicine" based on the molecular characterization of the tumor. In this new era it is becoming more and more clear that the monitoring of the disease is fundamental for the success of the treatment, thus there is the need of new biomarker discovery. More precisely in the last years the scientific community has started to use the term "liquid biopsy". A liquid biopsy is a liquid biomarker that can be easily isolated from many body fluids (blood, saliva, urine, ascites, pleural effusion, etc.) and, as well as a tissue biopsy,…

OncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsPleural effusionSettore MED/06 - Oncologia MedicaBiopsyexosomescirculating tumor cellsCirculating tumor cellSettore BIO/13 - Biologia ApplicataInternal medicineSettore BIO/10 - BiochimicaGeneticsmedicineBiomarkers TumorexosomeAnimalsHumanscancerBiomarker discoveryLiquid biopsyLung cancerBiologyliquid biopsybusiness.industryPhysicsCancerDNA Neoplasmmedicine.diseaseNeoplastic Cells CirculatingChemistryOncologyImmunologyBiomarker (medicine)Human medicinePersonalized medicineliquid biopsy; cancer; exosomes; circulating tumor cellsbusiness
researchProduct

Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models

2018

Patient-derived xenograft (PDX) models have become an important asset in translational cancer research. However, to provide a robust preclinical platform, PDXs need to accommodate the tumor heterogeneity that is observed in patients. Colorectal cancer (CRC) can be stratified into four consensus molecular subtypes (CMS) with distinct biological and clinical features. Surprisingly, using a set of CRC patients, we revealed the partial representation of tumor heterogeneity in PDX models. The epithelial subtypes, the largest subgroups of CRC subtype, were very ineffective in establishing PDXs, indicating the need for further optimization to develop an effective personalized therapeutic approach …

OncologyCancer Researchmedicine.medical_specialtyPartial representationColorectal cancerbusiness.industryTumor cellsmedicine.diseaseTumor heterogeneityTumor Subtype03 medical and health sciencesTherapeutic approach0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicineIn patientbusinessInternational Journal of Cancer
researchProduct

Technical Aspects for the Evaluation of Circulating Tumor Cells (CTCs)

2017

Liquid biopsy is considered a valid strategy to improve patients’ selection and treatment monitoring in clinical practice. Indeed Circulating Tumor Cells (CTCs) represent an important component of liquid biopsy and their clinical evaluation is becoming fundamental for a better patients’ stratification. Several techniques have been developed for CTCs isolation and enrichment and in this chapter we provide an updated overview of the main strategies that can be used.

OncologyClinical Practicemedicine.medical_specialtyCirculating tumor cellbusiness.industryInternal medicineMedicineLiquid biopsybusinessClinical evaluationCirculating Tumor CellsTreatment monitoring
researchProduct

Comparison of the combined action of oxaliplatin or cisplatin and radiation in cervical and lung cancer cells

2007

To test the combined effects of oxaliplatin and radiation versus cisplatin and radiation using human cervical and lung cancer cell lines.CaSki cervical cancer cells, and A549 lung cancer cells were cultured under standard conditions. Cells were treated with escalating doses of gamma-irradiation (0-6 Gy), and with oxali- and cisplatin for 2 h or 24 h, or a combination of both. Cell survival was measured by a colony-forming assay. Survival curves were fitted to the data using the linear quadratic model. Sensitizer enhancement ratios (SER) were calculated at the 37% survival level, and isobologram analysis was applied to test for the drug-radiation interactions.Oxaliplatin as well as cisplatin…

OncologyRadiation-Sensitizing Agentsmedicine.medical_specialtyLung NeoplasmsOrganoplatinum Compoundsmedicine.medical_treatmentUterine Cervical NeoplasmsAntineoplastic Agents03 medical and health sciences0302 clinical medicineInternal medicineTumor Cells CulturedmedicineHumansCytotoxic T cellRadiology Nuclear Medicine and imagingLung cancer030304 developmental biologyCisplatinA549 cellCervical cancer0303 health sciencesDose-Response Relationship DrugRadiological and Ultrasound Technologybusiness.industryDose-Response Relationship Radiationmedicine.diseaseCombined Modality Therapy3. Good healthOxaliplatinOxaliplatinRadiation therapy030220 oncology & carcinogenesisToxicityFemaleCisplatinbusinessmedicine.drugInternational Journal of Radiation Biology
researchProduct